-
Innovation Ranking
NewInnovation Ranking – Minerva Neurosciences Inc
Minerva Neurosciences Inc (Minerva Neurosciences) is a clinical-stage biopharmaceutical company that develops and commercializes a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The company's product candidates include MIN-101, a compound used for the treatment of patients with schizophrenia and MIN-117, a compound used for the treatment of patients suffering from major depressive disorder (MDD). It develops MIN-202, a selective orexin two (2) receptor antagonist used for the treatment of primary and secondary insomnia...
-
Product Insights
NewNet Present Value Model: Vigil Neuroscience Inc’s VGL-101
Empower your strategies with our Net Present Value Model: Vigil Neuroscience Inc's VGL-101 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Ochsner Health – Robert J. and Debra H. Patrick Neuroscience Center – Louisiana
The Ochsner Health – Robert J. and Debra H. Patrick Neuroscience Center – Louisiana project involves the construction of a 12,263m2 neuroscience center in New Orleans, Louisiana, the US. Equip yourself with the essential tools needed to make informed and profitable decisions with our Ochsner Health – Robert J. and Debra H. Patrick Neuroscience Center – Louisiana report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Not Disclosed Neuroscience And Pain 2 in Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Not Disclosed Neuroscience And Pain 2 in Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Not Disclosed Neuroscience And Pain 2 in Pain Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Not Disclosed Neuroscience And Pain 1 in Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Not Disclosed Neuroscience And Pain 1 in Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Not Disclosed Neuroscience And Pain 1 in Pain Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bexicaserin in Epileptic Encephalopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bexicaserin in Epileptic Encephalopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bexicaserin in Epileptic Encephalopathy Drug Details: LP-352 (AN-352) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bexicaserin in Tuberous Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bexicaserin in Tuberous Sclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bexicaserin in Tuberous Sclerosis Drug Details: LP-352 (AN-352) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bexicaserin in Lennox-Gastaut Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bexicaserin in Lennox-Gastaut Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bexicaserin in Lennox-Gastaut Syndrome Drug Details: LP-352 (AN-352) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bexicaserin in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bexicaserin in Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bexicaserin in Dravet Syndrome (Severe Myoclonic Epilepsy...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VG-3927 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VG-3927 in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VG-3927 in Alzheimer's Disease Drug Details: VG-3927 is under development for the...